



14 June 2017

ASX ANNOUNCEMENT

MACQUARIE UNIVERSITY COMMENCES LYMPHOEDEMA STUDY USING SOZO™

Brisbane, Australia and Carlsbad, Calif.- ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, is pleased to announce that Sydney's Macquarie University Hospital has commenced enrolment in the first planned clinical study using production SOZO™ units for lymphoedema. The aim of the study is to determine the best practices for at-home lymphoedema monitoring.

The study is being led by Ms Louise Koelmeyer, the Lymphoedema Program Manager of Macquarie University Hospital's ALERT (Australian Lymphoedema Education, Research & Treatment) program. The ALERT team aims to optimise positive outcomes for people living with lymphoedema through excellence in assessment and management of the condition along the continuum.

"The team at Macquarie University Hospital is a leading advocate for the use of L-Dex® to monitor cancer patients for lymphoedema. Recognising the potential for SOZO™ to improve the way patients are monitored and managed, Macquarie University has initiated this study to help establish how the at-home program is best implemented. Our aim is to detect lymphoedema at the earliest possible point in its development when its progression can be stopped or even reversed," said Richard Carreon, Managing Director & CEO of ImpediMed.

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.